Concord Wealth Partners Astrazeneca PLC Transaction History
Concord Wealth Partners
- $591 Million
- Q3 2024
A detailed history of Concord Wealth Partners transactions in Astrazeneca PLC stock. As of the latest transaction made, Concord Wealth Partners holds 2,221 shares of AZN stock, worth $145,764. This represents 0.03% of its overall portfolio holdings.
Number of Shares
2,221
Previous 2,170
2.35%
Holding current value
$145,764
Previous $169,000
2.37%
% of portfolio
0.03%
Previous 0.03%
Shares
13 transactions
Others Institutions Holding AZN
# of Institutions
1,359Shares Held
475MCall Options Held
5.39MPut Options Held
3.75M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.13 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$2.76 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.44 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.42 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.3MShares$1.27 Billion0.43% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $203B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...